2 completed, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow ACEi: new trials by email Literature Review of ACEi trials Research Report on ACEi
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts tacrolimus, Simulect, Cellcept - Kidney Transplantation | Phase 3 | Completed | Astellas Pharma Inc | 281 | 2009-08-17 | 2024-11-01 |
| Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy Mycophenolate Mofetil (MMF), MMF Placebo, ACEi - IgA Nephropathy | Phase 3 | Terminated | St. Joseph's Hospital and Medical Center, Phoenix | 184 | 2002-01-01 | 2016-03-07 |
| African American Study of Kidney Disease and Hypertension MAP goal less than or equal to 92 mm Hg, MAP goal 102-107 mm Hg, Ramipril - Hypertensive Nephrosclerosis, Chronic Renal Insufficiency | Phase 3 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1094 | 1995-02-01 | 2020-04-27 |
Glomerulonephritis, IGA (1) · Proteinuria (1) · Renal Insufficiency, Chronic (1)
Astellas Pharma Inc (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · St. Joseph's Hospital and Medical Center, Phoenix (1)
Canada (1) · United States (1)
PMID 11386927, PMID 12435255, PMID 20818902, PMID 30582281, PMID 38299639, PMID 38864363, PMID 39082471, PMID 39739990, PMID 41198855
U01DK048648 (1)